PATENT CLAIM ANALYSIS

Application Number: 16037282
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "133100"]

Abstract:
The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.

Claim (Index 10):
The method of  claim 9 , wherein the one or more fibrosis inhibitors are selected from the group consisting of a corticosteroid, an IL-1 receptor antagonist, a gamma interferon, or an antioxidant.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 95.0
- Lexical Diversity: 1.55814
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15520020', '15131312', '13485702', '15337113', '14054446']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7916130555010623
- 35 USC 102 Novelty (BERT): 0.6020143090155569
- Combined Prediction Score: 0.7726531808525118
- Mean Citation Score: 493.889634
- Max Citation Score: 602.3369
- Similarity Product: 432.61442663929466

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test